Buy, Sell or Hold: Microbix Biosystems (MBX-T) — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Microbix Biosystems (MBX-T)

TSE:MBX

0.34

0.02 (4.23%) 1d

Related posts

TSX hits new high, Wall St. climbs Biotechnology, Gene-editing and Medical Research Stocks to Buy in 2019 Earning Reports to Watch (Dec 17-21)

BUY

Very positive on the stock price, the company, and the partnerships they're announcing. Technicals indicate the stock may head toward 90 cents, but he says higher. Just won a contract from the Ontario government. Covid testing isn't going away. Sales should triple in the next 12 months.

biotechnology / pharmaceutical

TOP PICK

They're involved in Covid testing. Sales should more than double by Sept. 2021 year end to $25 million with a further 32% growth in sales of 2022 to $34 million. He expects Covid testing will continue to be common for employees and travellers. This stock could double from current levels. Other analysts target even higher, but this is a speculative stock. (Analysts’ price target is $0.80)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick May 17/19, Down 7%) He still holds this one. He participated in a financing about four months ago. They produce tests for HPV, but unfortunately COVID-19 has taken center stage. He likes their quality assessment tests and the outlook remains positive.

biotechnology / pharmaceutical

STRONG BUY

He still likes it and holds it. It makes cell culture measurements. They moved over to a more economical method for making their products and this will benefit their profitability. They have a division up for sale and they might get lucky and get a sale before year-end.

biotechnology / pharmaceutical

TOP PICK

A very thinly traded stock. They are involved in biomedical testing. They reported earnings up 40%. He sees great opportunity to increase capacity. He expects a 13 times PE going forward -- very reasonable. ROE 15%. His third largest holding. Yield 0% (Analysts’ price target is $0.71)

biotechnology / pharmaceutical

WEAK BUY

Doing a number of things in the animal area. Interested in it. There should be some dramatic catalysts this year.

biotechnology / pharmaceutical

WEAK BUY

Been around for a long time. Has a broad range of technologies. Have recently signed licensed for Virusmax, which can double the yield of virus production for vaccinations. Bull semen-sexing technology. Have some very interesting technologies. Watching it very closely. Like the company.

biotechnology / pharmaceutical

Showing 1 to 7 of 7 entries

«
‹
1
›
»

Microbix Biosystems(MBX-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Microbix Biosystems is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Microbix Biosystems(MBX-T) Frequently Asked Questions

What is Microbix Biosystems stock symbol?

Microbix Biosystems is a Canadian stock, trading under the symbol MBX-T on the Toronto Stock Exchange (MBX-CT). It is usually referred to as TSX:MBX or MBX-T

Is Microbix Biosystems a buy or a sell?

In the last year, there was no coverage of Microbix Biosystems published on Stockchase.

Is Microbix Biosystems a good investment or a top pick?

Microbix Biosystems was recommended as a Top Pick by on . Read the latest stock experts ratings for Microbix Biosystems.

Why is Microbix Biosystems stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Microbix Biosystems worth watching?

0 stock analysts on Stockchase covered Microbix Biosystems In the last year. It is a trending stock that is worth watching.

What is Microbix Biosystems stock price?

On 2024-04-19, Microbix Biosystems (MBX-T) stock closed at a price of $0.34.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.